Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $165.84 USD
Change Today +1.52 / 0.92%
Volume 401.0K
PRGO On Other Exchanges
Symbol
Exchange
Tel Aviv
Frankfurt
As of 2:59 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Open
$164.50
Previous Close
$164.32
Day High
$166.31
Day Low
$163.63
52 Week High
03/18/15 - $174.65
52 Week Low
05/8/14 - $125.37
Market Cap
23.3B
Average Volume 10 Days
1.2M
EPS TTM
$3.27
Shares Outstanding
140.8M
EX-Date
02/25/15
P/E TM
50.6x
Dividend
$0.50
Dividend Yield
0.27%
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services. The company’s Nutritionals segment offers infant and toddler formula products, infant and toddler foods, as well as vitamins, minerals, and dietary supplement products to retailers, distributors, and consumers. Its Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of Rx drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. This segment provides its products to chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. The company’s API segment develops, manufactures, and markets API that are used in the production of pharmaceutical products to generic drug industries and branded pharmaceutical companies. Its Specialty Sciences segment provides Tysabri, which is used for the treatment of Multiple Sclerosis; and Prialt, a non-narcotic intrathecal analgesic. The company also offers pharmaceutical and medical diagnostic products. The company offers its products primarily in the United States, the United Kingdom, Mexico, Israel, and Australia, as well as in Canada, China, and Latin America. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

10,220 Employees
Last Reported Date: 10/1/14
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $563.2K
Executive Vice President of Global Operations...
Total Annual Compensation: $470.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $470.3K
Executive Vice President and General Manager ...
Total Annual Compensation: $458.0K
Compensation as of Fiscal Year 2014.

perrigo co plc (PRGO) Key Developments

Perrigo Company Public Limited Company Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015

Perrigo Company Public Limited Company Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015 . Venue: JW Marriott Denver at Cherry Creek, 150 Clayton Lane, Denver, CO 80206, United States.

Perrigo Animal Health Launches Two New Product Lines

Perrigo Animal Health has launched two new product lines, Sentry Fiproguard Plus and Sentry Soft & Chewy Supplements, at the 2015 Global Pet Expo. Sentry Fiproguard Plus has the same active ingredients as Frontline Plus and includes fipronil and methoprene to protect against fleas, flea eggs, flea larvae, ticks and chewing lice. Sentry Soft & Chewy Supplements are offered in three varieties to help support the needs of dogs of all ages. Each option comes with 60 soft and chewy supplements.

Perrigo Company plc Showcases Two New Product Lines at the 2015 Global Pet Expo

Perrigo Animal Health, a division of Perrigo Company plc, showcased two new product lines at the 2015 Global Pet Expo: PetArmor Plus and PetArmor Soft & Chewy Supplements. PetArmor Plus has the same active ingredients as FRONTLINE Plus. It contains fipronil, the veterinarian-recommended active ingredient, and (s)-methoprene to protect against fleas, flea eggs, flea larvae, ticks and chewing lice. PetArmor Plus helps protect the entire family from illness by killing ticks that may transmit Lyme disease. Fast acting and long lasting, it stops the reinfestation cycle by killing flea eggs and larvae. PetArmor Soft & Chewy Supplements are available in three varieties to help support the unique needs of dogs of all ages. Each option comes with 60 soft and chewy supplements and features a tasty outside and healthy inside. PetArmor Calming Chews: helps to support calming in dogs with a unique pheromone-based formula. PetArmor Joint-Eze PLUS: promotes and maintains joint health with a four-in-one formula. PetArmor Joint-Eze ADVANCED: helps lubricate and ease stiff joints with a five-in-one formula.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $165.83 USD +1.51

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $90.22 USD +2.41
Hospira Inc $87.88 USD +0.03
Mead Johnson Nutrition Co $100.01 USD +0.70
Mylan NV $61.87 USD -0.01
Sun Pharmaceutical Industries Ltd 1,011 INR -16.50
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 64.0x
Price/Sales 5.4x
Price/Book 2.4x
Price/Cash Flow 66.8x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.